Tekla Healthcare Investors (HQH)
18.88
-0.14 (-0.74%)
USD |
NYSE |
Feb 01, 10:36
Price Chart
Key Stats
Customize
Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
1.19% | -9.86% | 999.08M | 185320.5 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
0% | 41.21% | -- | Upgrade |
Basic Info
Investment Strategy | |
The investment objective of the fund is to seek long-term capital appreciation by investing primarily in equity and related securities (including securities subject to legal or contractual restrictions on resale) of U.S. and foreign companies principally engaged in the healthcare industries ("Healthcare Companies"). The Fund will invest primarily in securities of U.S. and foreign companies that are generally believed by the Investment Adviser to have significant potential for above-average long-term growth in revenues and earnings. |
General | |
Security Type | Closed-End Fund |
Equity Style | Large Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | Tekla Capital Management LLC |
Prospectus Benchmark Index | |
NASDAQ Biotechnology TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Daniel Omstead | 21.27 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-2.908B
Category Low
7.616B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
Date Unavailable
Performance Versus Category
As of January 31, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of January 31, 2023.
Asset Allocation
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
Amgen Inc | 8.00% | 243.60 | -3.49% |
Vertex Pharmaceuticals Inc | 6.15% | 319.64 | -1.07% |
Gilead Sciences Inc | 5.70% | 83.44 | -0.60% |
Regeneron Pharmaceuticals Inc | 5.22% | 753.25 | -0.69% |
Horizon Therapeutics PLC | 3.54% | 110.40 | 0.62% |
AstraZeneca PLC ADR | 2.95% | 63.50 | -2.85% |
UnitedHealth Group Inc | 2.39% | 502.44 | 0.65% |
Seagen Inc Ordinary Shares | 2.27% | 137.08 | -1.72% |
AbbVie Inc | 2.18% | 146.07 | -1.14% |
Illumina Inc | 2.14% | 212.62 | -0.74% |
News
Headline
Wire
Time (ET)
SA Breaking News
03/14 00:40
Basic Info
Investment Strategy | |
The investment objective of the fund is to seek long-term capital appreciation by investing primarily in equity and related securities (including securities subject to legal or contractual restrictions on resale) of U.S. and foreign companies principally engaged in the healthcare industries ("Healthcare Companies"). The Fund will invest primarily in securities of U.S. and foreign companies that are generally believed by the Investment Adviser to have significant potential for above-average long-term growth in revenues and earnings. |
General | |
Security Type | Closed-End Fund |
Equity Style | Large Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | Tekla Capital Management LLC |
Prospectus Benchmark Index | |
NASDAQ Biotechnology TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Daniel Omstead | 21.27 yrs |
Fundamentals
General | |
Distribution Yield | Upgrade |
Dividend Yield TTM (2-1-23) | 0% |
30-Day SEC Yield | -- |
7-Day SEC Yield | -- |
Number of Holdings | Upgrade |
Stock | |
Weighted Average PE Ratio | 16.04 |
Weighted Average Price to Sales Ratio | Upgrade |
Weighted Average Price to Book Ratio | Upgrade |
Weighted Median ROE | Upgrade |
Weighted Median ROA | Upgrade |
Forecasted Dividend Yield | Upgrade |
Forecasted PE Ratio | Upgrade |
Forecasted Price to Sales Ratio | Upgrade |
Forecasted Price to Book Ratio | Upgrade |
As of June 30, 2022
Growth Estimates
Fund Details
Key Dates | |
Inception Date | 4/23/1987 |
Last Annual Report Date | 9/30/2022 |
Last Prospectus Date | 2/7/1997 |
Attributes | |
Index Fund | No |
Inverse Fund | No |
Leveraged Fund | No |
Fund of Funds | No |
Currency Hedged Fund | No |
Synthetic Replication Fund | No |
Has Dividend Investment Plan |
|
Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
03/14 00:40